Movement Alert｜XtalPi Holdings Rises 6.07% in Regular Trading, Life Sciences Sector Rally and Multiple Catalysts Drive Gains

Market Focus06-29 09:59

On June 29, XtalPi Holdings rose 6.07% in regular trading, trading at 7.25 HKD/share, with turnover of 231 million HKD.

On the news front, the company has recently released a cluster of positive developments. XtalPi announced a strategic partnership with an international biopharmaceutical company to co-develop oral small-molecule therapies targeting G protein-coupled receptors (GPCR), with a potential deal value exceeding $400 million including upfront payments, research funding, development and commercial milestone payments, and future royalties. The partner will fully fund XtalPi's early-stage R&D work. Simultaneously, the company launched a $100 million share buyback plan effective from June 10, signaling management confidence in the stock's valuation.

Additionally, national-level policy deployment for data-empowered AI development has boosted market expectations for a revaluation of the company's physical AI infrastructure capabilities. The broader life sciences sector rallied in tandem, with WuXi Biologics up 4.54%, Pharmaron up 4.57%, WuXi AppTec up 3.03%, and WuXi XDC up 3.27%, providing further sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192188163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192188163","market":"us","top_or_hot":-1,"title":"Movement Alert｜XtalPi Holdings Rises 6.07% in Regular Trading, Life Sciences Sector Rally and Multiple Catalysts Drive Gains","media":"Market Focus","content":"<p><p>On June 29, XtalPi Holdings rose 6.07% in regular trading, trading at 7.25 HKD/share, with turnover of 231 million HKD.</p><p>On the news front, the company has recently released a cluster of positive developments. XtalPi announced a strategic partnership with an international biopharmaceutical company to co-develop oral small-molecule therapies targeting G protein-coupled receptors (GPCR), with a potential deal value exceeding $400 million including upfront payments, research funding, development and commercial milestone payments, and future royalties. The partner will fully fund XtalPi's early-stage R&D work. Simultaneously, the company launched a $100 million share buyback plan effective from June 10, signaling management confidence in the stock's valuation.</p><p>Additionally, national-level policy deployment for data-empowered AI development has boosted market expectations for a revaluation of the company's physical AI infrastructure capabilities. The broader life sciences sector rallied in tandem, with WuXi Biologics up 4.54%, Pharmaron up 4.57%, WuXi AppTec up 3.03%, and WuXi XDC up 3.27%, providing further sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜XtalPi Holdings Rises 6.07% in Regular Trading, Life Sciences Sector Rally and Multiple Catalysts Drive Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜XtalPi Holdings Rises 6.07% in Regular Trading, Life Sciences Sector Rally and Multiple Catalysts Drive Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 09:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, XtalPi Holdings rose 6.07% in regular trading, trading at 7.25 HKD/share, with turnover of 231 million HKD.</p><p>On the news front, the company has recently released a cluster of positive developments. XtalPi announced a strategic partnership with an international biopharmaceutical company to co-develop oral small-molecule therapies targeting G protein-coupled receptors (GPCR), with a potential deal value exceeding $400 million including upfront payments, research funding, development and commercial milestone payments, and future royalties. The partner will fully fund XtalPi's early-stage R&D work. Simultaneously, the company launched a $100 million share buyback plan effective from June 10, signaling management confidence in the stock's valuation.</p><p>Additionally, national-level policy deployment for data-empowered AI development has boosted market expectations for a revaluation of the company's physical AI infrastructure capabilities. The broader life sciences sector rallied in tandem, with WuXi Biologics up 4.54%, Pharmaron up 4.57%, WuXi AppTec up 3.03%, and WuXi XDC up 3.27%, providing further sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1192188163","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192188163","pubTimestamp":1782698381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, XtalPi Holdings rose 6.07% in regular trading, trading at 7.25 HKD/share, with turnover of 231 million HKD.On the news front, the company has recently released a cluster of positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"动向提示|XtalPi Holdings常规交易涨6.07%生命科学板块涨势多重催化剂推动涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"On June 29, XtalPi Holdings rose 6.07% in regular trading, trading at 7.25 HKD/share, with turnover of 231 million HKD.On the news front, the company has recently released a cluster of positive developments. XtalPi announced a strategic partnership with an international biopharmaceutical company to co-develop oral small-molecule therapies targeting G protein-coupled receptors (GPCR), with a potential deal value exceeding $400 million including upfront payments, research funding, development and commercial milestone payments, and future royalties. The partner will fully fund XtalPi's early-stage R&D work. Simultaneously, the company launched a $100 million share buyback plan effective from June 10, signaling management confidence in the stock's valuation.Additionally, national-level policy deployment for data-empowered AI development has boosted market expectations for a revaluation of the company's physical AI infrastructure capabilities. The broader life sciences sector rallied in tandem, with WuXi Biologics up 4.54%, Pharmaron up 4.57%, WuXi AppTec up 3.03%, and WuXi XDC up 3.27%, providing further sector-wide momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192188163","isCrawlerRequest":true}